News

X‑Chem and Navitor Pharmaceuticals Enter into License Agreement on Novel Small Molecules Targeting mTORC1 Activation

March 31, 2015

WALTHAM & CAMBRIDGE, Mass. – March 30, 2015 –X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule…

News

X‑Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases

January 9, 2015

WALTHAM, Mass. – January 9, 2015 - X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today…

News

X‑Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer

January 9, 2015

WALTHAM, Mass. – January 9, 2015 - X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics,…